Related Experiment Video
Updated: Dec 17, 2025
08:57
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
2.4K
Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma
Noah E Berlow1,2,3, Catherine S Grasso3, Michael J Quist3
1Children's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.
Sarcoma
|June 23, 2020
Summary
This study explored personalized diagnostics and treatments for a rare soft-tissue sarcoma (STS) subtype. Despite advanced testing, including a patient-derived xenograft model, identified therapies were not clinically applied but offered potential FDA-approved regimens.
Area of Science:
- Oncology
- Genomics
- Proteomics
Background:
- Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a diverse group of rare cancers.
- Limited treatment options exist for many STS subtypes, particularly upon disease recurrence.
- Personalized therapy assignment is crucial when standard clinical options are exhausted.
Purpose of the Study:
- To investigate the utility of comprehensive personalized diagnostics in a patient with relapsed undifferentiated pleomorphic sarcoma (UPS).
- To explore potential therapeutic strategies based on advanced molecular and functional profiling.
Main Methods:
- The study involved a patient with relapsed UPS undergoing extensive diagnostics.
- Methods included genomic and proteomic profiling, ex vivo chemosensitivity testing, and a patient-derived xenograft (PDX) model.
- Immunoscoring and diverse therapeutic interventions (chemotherapy, radiation, surgery, immunotherapies, N-of-1 approaches) were employed.
Main Results:
- Advanced diagnostics identified potential personalized treatment options for the STS patient.
- The patient-derived xenograft model provided in vivo validation for some therapeutic strategies.
- Identified treatment regimens, while not directly implemented in clinical care, were based on FDA-approved agents.
Conclusions:
- Comprehensive personalized diagnostics, including PDX models, can generate plausible treatment options for rare cancers like UPS.
- Further research is needed to integrate findings from advanced preclinical models into clinical decision-making for STS patients.
- This case highlights the potential of personalized approaches to guide therapy when conventional treatments fail.
